3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Cyclophosphamide
22
Specimen Handling
20
Magnetic Resonance Spectroscopy
20
pembrolizumab
18
Nivolumab
18
Radiotherapy
17
Biopsy
16
Doxorubicin
15
Temozolomide
14
Radiation
14
X-Rays
9
Irinotecan
9
Ipilimumab
9
Ifosfamide
9
fludarabine
8
Phantoms, Imaging
8
Etoposide
8
cabozantinib
7
Vincristine
7
Carboplatin
7
Bevacizumab
7
regorafenib
6
Sirolimus
6
palbociclib
5
olaparib
5
fludarabine phosphate
5
durvalumab
5
Vinorelbine
5
Sunitinib
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Sarcoma
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled